Strasbourg, April 30, 2010 – Polyplus-transfection® SA, the privately-held company developing innovative solutions for molecular and cellular biology, today announced that its board has appointed Mark Bloomfield as CEO. Mark Bloomfield replaces Frédéric Perraud who continues with Polyplus-transfection as COO and Deputy CEO. This appointment takes place as Polyplus plans for accelerated revenue growth driven by the launch of new reagents and solutions for cell transfection applications, the commercialization of ZNA™ technology via licensing agreements with Sigma-Aldrich and Metabion as well as geographical sales channel expansion with partners in the United States and major European and Asian markets.
Mark Bloomfield, 51, with a background in chemistry, joins Polyplus-transfection after more than 15 years in senior sales, commercial leadership and business management positions with global companies in the biotechnology tools and analytical instruments space. Mark held a number of sales, sales management and business development roles with Hewlett-Packard, Agilent Technologies (Agilent spun out of HP), the Scientific Instruments Division of Thermo Electron (now Thermo Fisher Scientific) to the position of Division Vice-President Europe for Applied Biosystems’ Molecular & Cell Biology Business Unit.
“Polyplus has an outstanding track record in developing and commercializing innovative solutions for cell and molecular biologists and in providing them with both high quality products and with excellent technical support,” said Bloomfield. “I am delighted to be joining Polyplus and very much looking forward to using my business experience with the company’s team of scientists, marketers and sales professionals to continue and accelerate its growth.”
Mark Bloomfield will attend the 2010 BIO International Convention in Chicago, USA, May 3-6, Booth 3712, France Pavilion.
Polyplus-transfection – Mark Bloomfield (English version)